LAUSR

1 Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215–19. 2 Mankarious S, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 1988; 112: 634–40. 3 Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43: 1460–80. 4 Australian Red Cross Blood Service. Comparison of Intravenous Immunoglobulin Products available under National Blood Supply Arrangements from 1 November 2015; 2015 [cited 2015 Jan 16]. Available from URL: http://resources.transfusion.com.au/ cdm/ref/collection/p16691coll1/id/833 5 Bright PD, Smith L, Usher J, Donati M, Johnston SL, Gompels MM et al. False interpretation of diagnostic serology tests for patients treated with pooled human immunoglobulin G infusions: a trap for the unwary. Clin Med (Lond) 2015; 15: 125–9.